CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
monoclonal antibody +1 morebiological
Likely dose
chemotherapy 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00711191
NCT00711191Phase 1Completed
CompareCT.gov

A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer

Hoffmann-La Roche·interventional·Posted Jul 8, 2008·Updated Dec 24, 2013

In Brief

A Phase 1 clinical trial evaluating monoclonal antibody and chemotherapy for Pancreatic Neoplasm. Completed, enrolled 22 participants across 2 sites.

Detailed Summary

This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy. Preliminary evidence of clinical anti-tumor activity will be sought.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neoplasm
CountriesUnited States
CollaboratorsUniversity of Pennsylvania

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 8, 2008
Enrollment StartJun 1, 2008
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.0 years ago

Interventions

monoclonal antibodybiological

CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles

chemotherapydrug

gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles